Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose.

Authors :: Jessen, Bart A.
Cornwell, Paul
Redmond, Sean
Visalli, Thomas
Lemper, Marie
Bunch, Todd
Hart, Timothy
Source :: Cancer Chemotherapy & Pharmacology; Sep2024, Vol. 94 Issue 3, p1-1, 1p
Publication Year :: 2024

Subjects :: CANCER chemotherapy
SMALL molecules
INTELLIGENCE levels
ONCOLOGY

Full Text Access

Tools